Abstract
Rationale: Current GOLD strategy document positions both combination regimens of inhaled corticosteroid plus a long-acting β2-agonist [i.e. ICS/LABA] and long-acting muscarinic antagonist plus LABA [i.e. LAMA/LABA] for symptomatic patients with recurrent exacerbations. Methods: The InforMing the PAthway of COPD Treatment (IMPACT) study was a phase III, double-blind, parallel-group, multicenter study that compared the efficacy and safety of single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol 100/62.5/25µg (FF/UMEC/VI), FF/VI 100/25µg or UMEC/VI 62.5/25µg, all using the ELLIPTA® inhaler in symptomatic patients with COPD and exacerbation history, randomised 2:2:1, respectively to 52 weeks of treatment. The primary efficacy results on the annual rate of moderate or severe exacerbations are presented separately. Additional endpoints included change from baseline [CFB] in forced expiratory volume in 1s (trough FEV1), St George’s Respiratory Questionnaire (SGRQ) for FF/VI compared with UMEC/VI. Results: Of the 10 355 patients enrolled, 4134 received FF/VI and 2070 received UMEC/VI. At Week 52, there was a statistically significant improvement in trough FEV1 with UMEC/VI vs FF/VI (mean CFB 40mL and –3mL, treatment difference 43mL [95% CI: 28, 58mL]; p Conclusions: UMEC/VI improved lung function compared with the once daily ICS/LABA FF/VI in patients with symptomatic COPD and at risk of exacerbations whereas the SGRQ Total score was similar. These results may help to inform treatment choices for this patient population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have